Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial
There is a need for new pharmacological treatments for generalized social anxiety disorder (GSAD), which is a common, often disabling condition.
To compare the efficacy and safety over 6 months duration of two dose ranges of venlafaxine extended-release (ER) with placebo in patients with GSAD.
Twenty-eight-week, double-blind, multi-center study in 386 adult outpatients with DSM-IV GSAD. Patients were randomized to placebo, venlafaxine ER fixed low dose (75 mg/day), or venlafaxine ER flexible higher dose (150–225 mg/day). Primary efficacy variable was change on the Liebowitz Social Anxiety Scale (LSAS). Secondary efficacy variables included, among others, the proportion of responders on the CGI Global Improvement Item (score 1 or 2), and the proportion of remitters (defined as an LSAS score of ≤30).
Improvement on the LSAS was greater with venlafaxine ER (at 75 mg/day or 150–225 mg/day) than placebo, and was sustained throughout the 6-month trial. Of patients receiving venlafaxine ER (at any dose), 58% responded to treatment compared to 33% of those receiving placebo (P<0.001); corresponding remission rates were 31% and 16% (P<0.01). There were no differences in outcome according to venlafaxine ER dosage.
Venlafaxine ER was effective in the treatment of GSAD. The comparable efficacy at low and higher doses may indicate that norepinephrine reuptake blockade does not contribute to therapeutic effect in GSAD. This hypothesis should be tested using agents with specific actions on norepinephrine reuptake blockade.
KeywordsSocial phobia Anxiety disorder Pharmacotherapy Antidepressant
The authors are grateful to the investigators at the 19 sites who participated in this study (please see Appendix). Wyeth funded the study and supervised data collection and analyses. Drs. Stein, Pollack, and Kelsey are consultants to Wyeth, and Dr. Mangano is a Wyeth employee. Drs. Stein, Pollack, Bystritsky and Kelsey conduct clinical trials for and consult to numerous pharmaceutical companies.
- Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HGM (1999) Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 59:54–60Google Scholar
- Doyle AC, Pollack MH (2003) Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 64:40–45Google Scholar
- Guy W (1976) ECDEU Assessment manual for psychopharmacology (revised). DHEW Publications (ADM), Rockville, Md., National Institute for Mental HealthGoogle Scholar
- Kapczinski F, Lima MS, Souza JS, Schmitt R (2003) Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev CD003592Google Scholar
- Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1996) Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Psychopharmacol Bull 32:474Google Scholar
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janaversus J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22–33Google Scholar
- Stein MB, Sareen J, Hami S, Chao J (2001b) Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158:1727Google Scholar
- Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, Bystritsky A, Katon W, Sullivan G, Roy-Byrne PP (2004) Quality of care for primary care patients with anxiety disorders. Am J Psychiatry (in press)Google Scholar
- Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirschfeld RM, Lavange LM, Klein DN, Fawcett J, Harrison W (2002) Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59:233–239CrossRefPubMedGoogle Scholar
- Van Ameringen M, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavalle Y-J, Nandy S, Pecknold JC, Hadrava V, Swinson RP (2001) Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158:275–281CrossRefPubMedGoogle Scholar
- Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, Johnston DC, Lavallie YJ, Nandy S, Pecknold JC, Hadrava V, Lane RM (2000) Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20:636–644CrossRefPubMedGoogle Scholar